Cargando…

Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model

Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Su Jin, Lee, Kyoung Hwa, Kim, Jie-Hyun, Park, Soon Young, Song, Young Goo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460432/
https://www.ncbi.nlm.nih.gov/pubmed/32785101
http://dx.doi.org/10.3390/antibiotics9080502
_version_ 1783576600168628224
author Jeong, Su Jin
Lee, Kyoung Hwa
Kim, Jie-Hyun
Park, Soon Young
Song, Young Goo
author_facet Jeong, Su Jin
Lee, Kyoung Hwa
Kim, Jie-Hyun
Park, Soon Young
Song, Young Goo
author_sort Jeong, Su Jin
collection PubMed
description Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal microbiome composition in H. pylori-infected mice. To evaluate anti-H. pylori efficacy, mice were divided into eight groups, and H. pylori eradication was assessed by a Campylobacter-like organism (CLO) test and PCR assay of H. pylori in gastric mucosa. One week after H. pylori eradication, pro-inflammatory cytokine levels and atrophic changes in gastric mucosa were examined. Stool specimens were collected and analyzed for microbiome changes. The S-GM-based triple regimen decreased bacterial burden in vivo, compared with that in untreated mice or mice treated with other regimens. The therapeutic reactions in the CLO test from gastric mucosa were both 90% in the standard triple therapy and S-GM therapy group, respectively. Those of H. pylori PCR in mouse gastric mucosa were significantly lower in standard triple therapy and S-GM therapy groups than in the non-treatment group. Toxicity test results showed that S-GM therapy reduced IL-8 level and atrophic changes in gastric mucosa. Stool microbiome analysis revealed that compared with mice treated with the standard triple therapy, mice treated with the S-GM therapy showed microbiome diversity and abundant microorganisms at the phylum level. Our results suggested that S-GM is a promising and effective therapeutic agent against H. pylori infection.
format Online
Article
Text
id pubmed-7460432
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74604322020-09-03 Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model Jeong, Su Jin Lee, Kyoung Hwa Kim, Jie-Hyun Park, Soon Young Song, Young Goo Antibiotics (Basel) Article Helicobacter pylori eradication rate with conventional standard therapy is decreasing owing to antibiotic resistance, necessitating novel antibacterial strategies against H. pylori. We evaluated the efficacy of a gentamicin-intercalated smectite hybrid (S-GM)-based treatment and analyzed fecal microbiome composition in H. pylori-infected mice. To evaluate anti-H. pylori efficacy, mice were divided into eight groups, and H. pylori eradication was assessed by a Campylobacter-like organism (CLO) test and PCR assay of H. pylori in gastric mucosa. One week after H. pylori eradication, pro-inflammatory cytokine levels and atrophic changes in gastric mucosa were examined. Stool specimens were collected and analyzed for microbiome changes. The S-GM-based triple regimen decreased bacterial burden in vivo, compared with that in untreated mice or mice treated with other regimens. The therapeutic reactions in the CLO test from gastric mucosa were both 90% in the standard triple therapy and S-GM therapy group, respectively. Those of H. pylori PCR in mouse gastric mucosa were significantly lower in standard triple therapy and S-GM therapy groups than in the non-treatment group. Toxicity test results showed that S-GM therapy reduced IL-8 level and atrophic changes in gastric mucosa. Stool microbiome analysis revealed that compared with mice treated with the standard triple therapy, mice treated with the S-GM therapy showed microbiome diversity and abundant microorganisms at the phylum level. Our results suggested that S-GM is a promising and effective therapeutic agent against H. pylori infection. MDPI 2020-08-10 /pmc/articles/PMC7460432/ /pubmed/32785101 http://dx.doi.org/10.3390/antibiotics9080502 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jeong, Su Jin
Lee, Kyoung Hwa
Kim, Jie-Hyun
Park, Soon Young
Song, Young Goo
Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title_full Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title_fullStr Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title_full_unstemmed Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title_short Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model
title_sort efficacy and gut dysbiosis of gentamicin-intercalated smectite as a new therapeutic agent against helicobacter pylori in a mouse model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460432/
https://www.ncbi.nlm.nih.gov/pubmed/32785101
http://dx.doi.org/10.3390/antibiotics9080502
work_keys_str_mv AT jeongsujin efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel
AT leekyounghwa efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel
AT kimjiehyun efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel
AT parksoonyoung efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel
AT songyounggoo efficacyandgutdysbiosisofgentamicinintercalatedsmectiteasanewtherapeuticagentagainsthelicobacterpyloriinamousemodel